Subsequent to its commitment last fall to find a development partner (The Pharma Letter October 5, 2015), US biopharma company XenoPort (Nasdaq: XNPT) has entered into a license agreement under which Indian drug major Dr Reddy’s Laboratories (BSE: 500124) will be granted exclusive US rights for the development and commercialization of XenoPort’s clinical-stage oral new chemical entity, XP23829.
XenoPort’s shares gained more than 4.8% to $4.56 by midday Monday on the news, while Dr Reddy’s was barely changed.
Dr Reddy’s plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis and may potentially develop XP23829 for relapsing forms of multiple sclerosis (MS).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze